Table 1.
Demographic, clinical and biomarker data using diagnoses obtained prior to [18F]flutemetamol PET
| MCI | AD | Non-AD disorder | Dementia NOS | SCD | ||
|---|---|---|---|---|---|---|
| Number of patients | 131 | 41 | 10 | 20 | 5 | |
| Age (years), mean (SD) | 64.5 (8.6) | 65.2 (8.7) | 67.6 (5.2) | 62.3 (9.5) | 68.4 (8.3) | |
| Sex, female/male (n/n) | 76/55 | 27/14 | 5/5 | 10/10 | 3/2 | |
| MMSEa | 25.6 (3.7) | 24.5 (3.7) | 23.4 (3.8) | 22 (5.5) | 29 (1.2) | |
| APOE ε4 | ||||||
| Number of patients with data available | 75 | 27 | 4 | 9 | 5 | |
| Number (%) positive | 42 (56) | 15 (56) | 2 (50) | 2 (22) | 2 (40) | |
| CSF biomarkers | ||||||
| Number of patients with data available | 86 | 38 | 9 | 15 | 4 | |
| Aβ1-42 (ng/L), mean (SD) | 595 (164) | 612 (325) | 627 (198) | 678 (272) | 685 (98.4) | |
| p-tau (ng/L), mean (SD)b | 52 (29) | 59 (23) | 49 (23) | 39.9 (24.5) | 73 (19.8) | |
| t-tau (ng/L), mean (SD)c | 369 (228) | 429 (201) | 506 (152) | 299 (289) | 549 (241) | |
| CT/MRI scales | ||||||
| Number of patients with data available | 128 | 40 | 10 | 19 | 5 | |
| MTA (n)d | 0/1k | 76 | 20 | 2 | 10 | 5 |
| 2 | 39 | 14 | 5 | 6 | 0 | |
| 3 | 11 | 5 | 2 | 2 | 0 | |
| 4 | 2 | 1 | 1 | 1 | 0 | |
| GCA (n)e | 0 | 32 | 8 | 1 | 4 | 0 |
| 1 | 75 | 25 | 5 | 9 | 3 | |
| 2 | 20 | 7 | 3 | 5 | 2 | |
| 3 | 1 | 0 | 1 | 1 | 0 | |
| Fazekas scale (n)f | 0 | 28 | 7 | 1 | 3 | 0 |
| 1 | 68 | 21 | 6 | 10 | 4 | |
| 2 | 21 | 8 | 2 | 1 | 1 | |
| 3 | 11 | 4 | 1 | 5 | 0 | |
| [18F]FDG metabolic patternsg | ||||||
| Number of patients with data available | 44 | 16 | 4 | 11 | 3 | |
| Typical of AD (n) | 4 | 2 | 0 | 0 | 0 | |
| Not typical of AD (n) | 16 | 9 | 0 | 5 | 0 | |
| Non-AD (n) | 13 | 3 | 2 | 5 | 0 | |
| Nonspecific (n) | 11 | 2 | 2 | 1 | 3 | |
| [18F]Flutemetamol | ||||||
| Number (%) positive on visual assessmenth | 69 (53) | 28 (68) | 2 (20) | 4 (20) | 3 (60) | |
| Global SUVR, mean (SD)I | 0.61 (0.19) | 0.71 (0.18) | 0.47 (0.05) | 0.52 (0.18) | 0.64 (0.18) | |
| Number (%) positive by SUVRj | 67 (51) | 28 (68) | 2 (20) | 4 (20) | 3 (60) | |
AD Alzheimer’s disease, GCA global cortical atrophy, MCI mild cognitive impairment, MMSE Mini-Mental State Examination, MTA medial temporal atrophy, NOS not otherwise specified, SCD subjective cognitive decline, SUVR standardized uptake value ratio
aMMSE: dementia NOS < AD (p < 0.01); MCI, AD, non-AD, dementia NOS < SCI (p < 0.01)
b p-tau AD > MCI and dementia NOS (p < 0.05); SCI > dementia NOS (p < 0.05)
ct-tau: AD > dementia NOS (p < 0.01)
dMTA (0/1 none/minimal, 2 mild, 3 moderate, 4 severe): MCI vs. non-AD (p < 0.01); AD vs. non-AD (p < 0.01); non-AD vs. dementia NOS (p < 0.05)
eGCA: 0 none, 1 mild, 2 moderate, 3 severe
fFazekas scale (white matter hyperintensities): 0 none, 1 mild, 2 moderate, 3 severe
g[18F]FDG metabolic patterns: AD vs. SCI (p < 0.05), dementia NOS vs. SCI (p < 0.01)
hVisual assessment: MCI > dementia NOS (p < 0.01), AD > non-AD (p < 0.01), AD > dementia NOS (p < 0.001)
ISUVR: MCI > dementia NOS (p < 0.05), AD > MCI (p < 0.01), non-AD (p < 0.01), dementia NOS (p < 0.001)
jSUVR positivity (SUVR defined using a global cortical cut-off value of >0.60): MCI > dementia NOS (p < 0.01), AD > non-AD (p < 0.01) AD > dementia NOS (p < 0.001)
kMTA 0 and 1 are considered normal; these categories were therefore combined